Skip to Content
Stock Analyst Update

Biogen's Alzheimer's Drug Doesn't Win Committee Support

We're lowering our fair value estimate for the wide-moat drug manufacturer.

Mentioned:

We're lowering our fair value estimate for Biogen (BIIB) from $354 to $346 following a Food and Drug Administration advisory committee meeting that was highly skeptical of Biogen's regulatory filing for Alzheimer's disease drug candidate aducanumab. The sentiment of the committee, evidenced in their discussion and several votes throughout the Nov. 6 meeting, appears to run counter to the Food and Drug Administration's stated position in briefing documents released on Nov. 4. While trading in Biogen shares was halted on Friday during the meeting, we expect shares to decline significantly when trading resumes on Monday. Following the largely positive briefing documents and largely negative committee meeting, we continue to assume a 40% probability of approval for aducanumab, but we now expect the FDA will require another phase 3 study before approving aducanumab. Assuming Biogen could initiate such a study in 2021, we would expect the firm could have data by the end of 2023, with potential approval in 2024. This results in sales climbing as high as $6 billion, if approved, by 2029. We don't think Biogen's wide moat hangs in the balance, as this is supported by a diverse multiple sclerosis portfolio, newer drug Spinraza, a growing biosimilar portfolio, and a deep pipeline in neurodegenerative diseases.

Despite the sharply negative vote, the FDA could still approve the drug on schedule (by March 2021) if they opt to require an additional study to be conducted post-approval. Even though the gold standard for an application for approval of an Alzheimer's drug is two large efficacy studies, the FDA has previously shown some flexibility with other approvals in neurology, particularly when unmet need is high and other supportive evidence exists. That said, Alzheimer's disease affects millions of patients, and widespread use of an ineffective therapy would be costly on many levels. Approving a drug despite such strong dissent from the committee seems difficult to support.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Karen Andersen does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.